41 terminated. 41 Phase 2, 7 Phase 3, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 41 | Terminated 41 |
| Phase 3 | 7 | Terminated 7 |
| Phase 1 | 4 | Terminated 4 |
Follow Shock: new trials by email Literature Review of Shock trials Research Report on Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care 101-PGC-005 ('005) + SOC, Placebo + SOC - COVID-19 | Phase 2 | Terminated | 101 Therapeutics | 3 | 2022-01-13 | 2023-02-24 |
| Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults Maraviroc + Currently used therapy, Curently used therapy for COVID-19 non-critical patients, Favipiravir + Currently used therapy - COVID-19 | Phase 2 | Terminated | Hospital General de México Dr. Eduardo Liceaga | 19 | 2021-07-13 | 2022-06-03 |
| RAPA-501-Allo Therapy of COVID-19-ARDS RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo - Severe COVID-19 Disease | Phase 1 / Phase 2 | Terminated | Rapa Therapeutics LLC | 1 | 2020-12-30 | 2021-11-11 |
| INB03 for the Treatment of Pulmonary Complications From COVID-19 INB03, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Inmune Bio, Inc. | 79 | 2020-10-21 | 2026-05-19 |
| Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome dapansutrile capsules, placebo capsules - Covid19, Cytokine Release Syndrome | Phase 2 | Terminated | Olatec Therapeutics, Inc. | 49 | 2020-09-24 | 2023-04-13 |
| A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients OP-101, Placebo - COVID-19 | Phase 2 | Terminated | Ashvattha Therapeutics, Inc. | 28 | 2020-08-11 | 2023-02-13 |
| Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Conestat alfa - Coronavirus Infections | Phase 2 | Terminated | University Hospital, Basel, Switzerland | 80 | 2020-08-06 | 2021-11-09 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 Hyperbaric oxygen - SARS (Severe Acute Respiratory Syndrome), Cytokine Storm | Phase 2 / Phase 3 | Terminated | Karolinska Institutet | 34 | 2020-06-03 | 2023-01-09 |
| A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 SNDX-6352, Placebo - Coronavirus, COVID | Phase 2 | Terminated | Syndax Pharmaceuticals | 1 | 2020-05-30 | 2022-07-22 |
| Colchicine in Patients With Mild and Severe Coronavirus Disease Colchicine, Placebo oral tablet - COVID | Phase 2 | Terminated | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 116 | 2020-05-27 | 2022-08-10 |
| Prazosin to Prevent COVID-19 (PREVENT-COVID Trial) Prazosin, Standard of care - COVID-19 | Phase 2 | Terminated | Johns Hopkins University | 5 | 2020-05-13 | 2023-04-10 |
| Etoposide in Patients With COVID-19 Infection Etoposide - COVID-19 | Phase 2 | Terminated | Boston Medical Center | 8 | 2020-05-08 | 2023-06-15 |
| Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19 Tocilizumab 180 MG/ML, Methylprednisolone Sodium Succinate - Cytokine Release Syndrome, Covid-19 | Phase 2 | Terminated | Hospital Sao Domingos | 30 | 2020-05-01 | 2022-03-29 |
| Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 Naltrexone, Ketamine, Placebo - COVID-19, Acute Respiratory Distress Syndrome | Phase 2 | Terminated | Corewell Health East | 70 | 2020-04-29 | 2022-01-26 |
| Early Metabolic Resuscitation for Septic Shock Best Practice, early metabolic resuscitation - Multiple Organ Failure, Septic Shock | Phase 2 | Terminated | M.D. Anderson Cancer Center | 2 | 2019-10-04 | 2024-10-29 |
| ASpirin for Patients With SEPsis and SeptIc Shock Aspirin - Sepsis | Phase 2 | Terminated | Federal University of São Paulo | 167 | 2019-03-27 | 2023-07-13 |
| The Val-CARD Trial Sodium Valproate - Cardiac Valve Disease, Coronary Artery Disease | Phase 1 / Phase 2 | Terminated | University of Leicester | 45 | 2018-11-06 | 2026-08-17 |
| Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock Stress-dose Hydrocortisone plus Vitamin C, isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo - Septic Shock | Phase 1 / Phase 2 | Terminated | University of Athens | 26 | 2018-09-06 | 2024-12-19 |
| Vitamin C, Hydrocortisone and Thiamine for Septic Shock Combined Vitamin C and Stress-Dose Hydrocortisone, Placebo plus placebo - Shock, Septic | Phase 2 | Terminated | University of Athens | 24 | 2018-09-06 | 2024-12-19 |
Showing 20 of 41. Sign in to see all of them.
Cytokine Release Syndrome (15) · Shock, Septic (14) · COVID-19 (13) · Coronavirus Infections (7) · Respiratory Distress Syndrome (6) · Sepsis (5) · Multiple Organ Failure (4) · Systemic Inflammatory Response Syndrome (3) · Critical Illness (2) · Heart Arrest (2) · Hypotension (2) · Inflammation (2) · Pneumonia (2) · Severe Acute Respiratory Syndrome (2)
Pathologic Processes (41) · Pathological Conditions, Signs and Symptoms (41) · Inflammation (30) · Infections (29) · Systemic Inflammatory Response Syndrome (29) · Coronaviridae Infections (15) · Nidovirales Infections (15) · RNA Virus Infections (15) · Virus Diseases (15) · Pneumonia, Viral (13) · Respiratory Tract Diseases (13) · Respiratory Tract Infections (13) · Lung Diseases (12) · Pneumonia (11)
Saline Solution (4) · Ascorbic Acid (3) · Standard of Care (3) · Heparin (2) · Resuscitation (2) · Sodium Chloride (2) · Thiamine (2) · Tranexamic Acid (2) · Adrenergic alpha-1 Receptor Antagonists (1) · Adrenergic alpha-Antagonists (1) · Adrenergic beta-Antagonists (1) · Aspirin (1) · Clonidine (1) · Colchicine (1) · Cool-Down Exercise (1)
Beth Israel Deaconess Medical Center (2) · Corewell Health East (2) · University of Athens (2) · 101 Therapeutics (1) · Ashvattha Therapeutics, Inc. (1) · Boston Medical Center (1) · Centre Hospitalier Régional d'Orléans (1) · Changhua Christian Hospital (1) · Danish Procalcitonin Study Group (1) · Denver Health and Hospital Authority (1) · Direction Centrale du Service de Santé des Armées (1) · Faron Pharmaceuticals Ltd (1) · Federal University of São Paulo (1) · Ferring Pharmaceuticals (1) · Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz (1)
United States (24) · Brazil (4) · Canada (3) · France (3) · Greece (3) · Mexico (3) · Belgium (2) · Denmark (2) · Netherlands (2) · Spain (2) · Switzerland (2) · United Kingdom (2) · Estonia (1) · Finland (1) · Germany (1)
Adelina Pellicer, MD PhD (1) · Adham Mohamed, PharmD (1) · Anand Kumar, MD (1) · Anastasia Kotanidou, MD, PHD, Professor (1) · Anastasia Kotanidou, MD, PhD (1) · Anders Kjellberg, MD (1) · Chetan Bettegowda, MD/PhD (1) · Daniel Fowler, M.D. (1) · Dean A Fergusson, PhD MHA (1) · Erik B Kistler, MD, PhD (1) · Ernest E Moore, MD (1) · Flavia Machado (1) · Gavin Murphy, MD (1)
PMID 10722036, PMID 1138591, PMID 11502226, PMID 12454520, PMID 12545007, PMID 12700374, PMID 1607900, PMID 16570523, PMID 18353115, PMID 20332511, PMID 20646908, PMID 21864392, PMID 227054, PMID 23525934, PMID 24484547, PMID 24838355, PMID 25466837, PMID 25784527, PMID 26220293, PMID 26771781, PMID 26903338, PMID 27162802, PMID 27695824, PMID 27940189, PMID 28098591, PMID 29325753, PMID 29388815, PMID 30032977, PMID 30271882, PMID 31577035, PMID 31851290, PMID 33397449, PMID 34226219, PMID 34473343, PMID 34755269, PMID 35063229, PMID 35066509, PMID 35115574, PMID 36870070, PMID 37510965, PMID 37965347, PMID 3928249, PMID 39393522, PMID 39982179, PMID 40766812, PMID 40983029, PMID 8615361, PMID 8625625
2014 (2), 2018 (1), K23HL096054 (1), K23HL128814 (1), P30CA016672 (1)